LVIP07-SD1-CS1, F2-CTS-ABCA4-CS1, Clone 19
The cell line is not validated yet.
LVPEIi001-C-1
General
iPSC Line |
|
| hPSCreg name | LVPEIi001-C-1 |
| Cite as: | LVPEIi001-C-1 |
| Alternative name(s) |
LVIP07-SD1-CS1, F2-CTS-ABCA4-CS1, Clone 19
|
| iPSC line type | Human induced pluripotent stem cell (hiPSC) |
| Similar iPSC lines | No similar lines found. |
| Last update | 26th May 2026 |
| Notes | This is an isogenic, ABCA4 gene edited mutant iPSC line derived from the healthy control iPSC line, LVPEIi001-C. It was generated using an exon 44 targeting sgRNA and an engineered en1FnCas9 encoded CRISPR construct. It carries a 12-base pair deletion within the exon 44 of both the alleles of ABCA4 gene. This homozygous genomic edit was confirmed by target-region specific PCR amplification and Sanger sequencing of the genomic DNA. The in-frame deletion resulted in the loss of 4 amino acids within the second nucleotide-binding domain 2 (NBD2) of ABCA4, which causes structural defects that could impair the protein function. The isogenic line was clonally expanded beyond passage 20. This clonal line maintained the expression of major stemness markers (OCT4, SOX2, NANOG, KLF4, SSEA4), demonstrated the ability to differentiate into all three germ layers and exhibited a normal female karyotype. |
| User feedback | |
Provider |
|
| Generator |
L.V. Prasad Eye Institute (LVPEI)
Contact:
L.V. Prasad Eye Institute (LVPEI) |
| Owner | L.V. Prasad Eye Institute (LVPEI) |
| Distributors | |
| Derivation country | India |
External iPSC Databases |
|
| BioSamples | SAMEA117637585 |
General iPSC Information |
|
| * Is the cell line readily obtainable for third parties? |
Yes Research use: allowed
Clinical use: not allowed
Commercial use: allowed
|
| Subclone of | |
iPSC Genetic Modification
| Genetic modifications not related to a disease |
|
Donor Information
General Donor Information |
|
| Sex | female |
| Ethnicity | Asian Indian (35 years old) |
Phenotype and Disease related information (Donor) |
|
| Diseases | No disease was diagnosed.
|
| Family history | No inherited or systemic disease pathology reported. |
Other Genotyping (Donor) |
|
| Is there genome-wide genotyping or functional data available? |
No
|
Donor Relations |
|
| Other cell lines of this donor | |
External Databases (Donor) |
|
| BioSamples | SAMEA14207086 |
Ethics
Also have a look at the ethics information for the parental line
LVPEIi001-C
.
| Is there an MTA available for the cell line? | Yes |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? | The gene editing vector plasmid, FnCas9en1, was obtained from the collaborator Dr. Debojyoti Chakraborty's lab at IGIB. The ABCA4 gene targeting CRISPR guide DNA oligos was then cloned into the BbsI site, downstream of the U6 promoter. |
| Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? | Yes |
| Constraints for use or distribution | For research use only |
iPSC Derivation
General |
|
|
The source cell information can be found in the parental cell line
LVPEIi001-C.
|
|
Reprogramming method |
|
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
iPSC Culture Conditions
iPSC Characterisation
Analysis of undifferentiated iPSCs
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| POU5F1 (OCT-4) |
Yes |
Score:
| Marker | Present | Absent |
| mCpG | ||
| OCT4 |
Morphology pictures
Differentiation Potency
In vitro spontaneous differentiation
| Marker | Expressed |
| AFP |
Yes |
| FOXA1 |
Yes |
Morphology
In vitro spontaneous differentiation
Microbiology / Virus Screening |
|
Genotyping
Karyotyping (iPSC Line) |
|
| Has the iPSC line karyotype been analysed? |
Yes
46, XX
Passage number: 15
Karyotyping method:
G-Banding
|
Other Genotyping (iPSC Line) |
|
Login to share your feedback, experiences or results with the research community.